Month: March 2023

GROSSE POINTE FARMS, Mich., March 09, 2023 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) (the “Company” or “Saga”) reported today that net revenue increased 6.0% to $114.9 million for the twelve-month period ended December 31, 2022 compared to $108.3 million for the same period last year. Despite strong underlying performance the results were impacted by one-time payments during the 3rd Quarter related to the passing in August of our founder Ed Christian. The actual results as well as the results adjusted for the impact of his passing are reported in this financial results release. Station operating expense increased 5.2% for the twelve-month period to $87.5 million compared to the same period last year. For the twelve-month period, station operating income increased 5.7% to $32.3 million and operating income...

Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others. Thursday, March 23, 2023, 4:30 PM ETDomestic:                   877-269-7756International:              201-689-7817Conference ID:           13736454Webcast:                    GeoVax 2022...

FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update. Fourth Quarter and Recent Corporate HighlightsPresented preclinical data on the CLR 12120 series of targeted alpha therapies (TATs) at the 13th Annual World ADC Conference. The presentation, entitled: “Novel Conjugates – Radiotherapies,” given by Cellectar’s Chief Operating Officer, Jarrod Longcor, highlighted data demonstrating the versatility of the phospholipid ether (PLE) targeting platform and the potential of the company’s alpha emitting precision medicines, supporting further development.Announced...

Fourth-Quarter 2022: Revenue of $8.4 million, a 17% increase over Q4 2021Full-Year 2022: Revenue of $30.5 million, a 17% increase over 2021 HOPEWELL JUNCTION, N.Y., March 09, 2023 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a U.S.-based leader in the development, design and manufacture of Active Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its fourth quarter and full-year 2022. Fourth Quarter and Full-Year HighlightsFourth-quarter 2022 revenue of $8.4 million, a 17% increase over the fourth quarter of 2021 Full-year 2022 revenue of $30.5 million, a 17% increase over full-year 2021 Achieved positive EBITDA for the fourth quarter and the full year of 2022 As of December 31, 2022, strong backlog of open orders of $14.8 million,...

Year Over Year Revenues Track the Five Year Plan by Increasing 21% ($45 million) to $257 Million CUPERTINO, CA, March 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire –Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on below zero carbon intensity products, today announced its financial results for the three and twelve months ended December 31, 2022. “Revenues for 2022 increased 21% compared to 2021, largely due to price increases in ethanol feed co-products in the United States and demand from oil marketing companies in India,” said Todd Waltz, Chief Financial Officer of Aemetis.  “Revenues during 2022 increased to $257 million compared to $212 million during 2021. Capital expenditures for carbon intensity reduction projects were $49.5 million for 2022 as our engineering and construction...

CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December 31, 2022 and provided an update on recent business developments and Company progress. Blue Water Vaccines is a preclinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (“AOM”) and pneumonia from Streptococcus pneumoniae colonization, influenza, norovirus, rotavirus, monkeypox, Marburg virus disease and Chlamydia. “In addition to our successful initial public offering and raising subsequent capital to extend our runway, we made significant corporate progress and further developed our vaccine candidates throughout the year,” said Joseph Hernandez, Chairman and Chief Executive...